Fifty-two, Hereford heifers were obtained from brucellosis-free herds and randomly assigned to Brucella abortus strain RB51 (RB51) vaccination (n = 32) or control (n = 20) treatments. Vaccinates received 1010 colony-forming units (CFU) of a commercial lyophilized RB51 vaccine. Immunologic responses after inoculation demonstrated significantly greater (P < 0.05) antibody, interferon-γ responses, and proliferative responses to RB51 antigens in cattle vaccinated with RB51 as compared to controls. A subgroup of control and vaccinated cattle were experimentally challenged at approximately 4, 5, and 6 years after inoculation with 107 CFU of B. abortus strain 2308 at 170–180 days gestation. After experimental challenge, 6 of 14 (43 %) control animals aborted at a higher rate (P < 0.05) when compared to RB51 vaccinates in years 4 and 5, but not year 6 (0 %, 10 %, and 50 %, respectively). When comparing recovery of Brucella from all tissues except head lymph nodes draining the site of challenge, RB51 vaccinates had reduced infection rates (P < 0.05) after experimental challenge at 4 years (14 %), but not at 5 or 6 years (78 % and 67 %, respectively) when compared to non-vaccinated cattle (93 %). Our data suggests that calfhood vaccination with RB51 does not induce lifelong immunity and suggests implementation of booster vaccination by 4–5 years of age should be utilized in endemic areas to maintain high levels of protection.
Read full abstract